Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Myeloid Leukemia ◽

Low Dose ◽

Newly Diagnosed ◽

Low Dose Cytarabine ◽

Faculty Opinions recommendation of A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119427.575617 ◽

2008 ◽

Author(s):

Arati Rao

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

Randomized Study ◽

Front Line ◽

Line Therapy ◽

Low Dose Cytarabine ◽

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

Leukemia & Lymphoma ◽

10.3109/10428194.2012.737917 ◽

2012 ◽

Vol 54 (4) ◽

pp. 760-766 ◽

Cited By ~ 30

Author(s):

David A. Macdonald ◽

Sarit E. Assouline ◽

Joseph Brandwein ◽

Suzanne Kamel-Reid ◽

Elizabeth A. Eisenhauer ◽

...

Keyword(s):

Clinical Trials ◽

Acute Myeloid Leukemia ◽

High Risk ◽

Elderly Patients ◽

Myeloid Leukemia ◽

Low Dose ◽

Group Trial ◽

Low Dose Cytarabine ◽

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

Annals of Hematology ◽

10.1007/s00277-020-04291-0 ◽

2020 ◽

Author(s):

Márcio Tavares ◽

Sérgio Chacim ◽

José Mário Mariz

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

Compassionate Use ◽

Refractory Acute Myeloid Leukemia ◽

Low Dose Cytarabine ◽

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Cancer ◽

10.1002/cncr.22496 ◽

2007 ◽

Vol 109 (6) ◽

pp. 1114-1124 ◽

Cited By ~ 396

Author(s):

Alan K. Burnett ◽

Donald Milligan ◽

Archie G. Prentice ◽

Anthony H. Goldstone ◽

Mary F. McMullin ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Retinoic Acid ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Low Dose Cytarabine ◽

A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.6537 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 6537-6537

Author(s):

J. Butera ◽

E. Winer ◽

C. Wang ◽

J. J. Castillo ◽

A. G. Thomas ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Low Dose ◽

Phase Ii Study ◽

Myelogenous Leukemia ◽

Acute Myelogenous ◽

Low Dose Cytarabine ◽

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Haematologica ◽

10.3324/haematol.2017.168732 ◽

2017 ◽

Vol 102 (10) ◽

pp. 1709-1717 ◽

Cited By ~ 11

Author(s):

Naval Daver ◽

Hagop Kantarjian ◽

Guillermo Garcia-Manero ◽

Elias Jabbour ◽

Gautam Borthakur ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Older Patients ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

Leukemia ◽

10.1038/leu.2015.244 ◽

2015 ◽

Vol 30 (2) ◽

pp. 268-273 ◽

Cited By ~ 40

Author(s):

N Daver ◽

H Kantarjian ◽

F Ravandi ◽

E Estey ◽

X Wang ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Phase Ii ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

Gemtuzumab Ozogamicin ◽

Newly Diagnosed ◽

Relapsed Acute Myeloid Leukemia ◽

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Case Medical Research ◽

10.31525/ct1-nct04241549 ◽

2020 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Intensive Treatment ◽

Newly Diagnosed ◽

GRASPA-AML 2012-01 study (NCT01810705): A multicenter, open, randomized phase 2b trial evaluating ERY001 (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps7099 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS7099-TPS7099 ◽

Cited By ~ 1

Author(s):

Xavier G. Thomas ◽

Emmanuelle Tavernier Tardy ◽

Romain Guieze ◽

Patrice Chevallier ◽

Jean pierre Marolleau ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Elderly Patients ◽

Red Blood Cells ◽

Blood Cells ◽

Myeloid Leukemia ◽

Low Dose ◽

Intensive Chemotherapy ◽

Newly Diagnosed ◽

Low Dose Cytarabine ◽

Long‐term Results of Low‐intensity Chemotherapy with Clofarabine or Cladribine Combined with Low‐Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

American Journal of Hematology ◽

10.1002/ajh.26206 ◽

2021 ◽

Author(s):

Tapan M. Kadia ◽

Farhad Ravandi ◽

Gautam Borthakur ◽

Marina Konopleva ◽

Courtney D. DiNardo ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Older Patients ◽

Myeloid Leukemia ◽

Low Dose ◽

Long Term Results ◽

Newly Diagnosed ◽

Low Intensity ◽

Low Dose Cytarabine ◽